Maze Therapeutics Inc (MAZE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 52,231 | 81,810 | 106,562 | -32,494 | -100,415 |
| Depreciation Amortization | 3,297 | 2,592 | 1,804 | 950 | 4,089 |
| Accounts payable and accrued liabilities | -204 | -1,025 | 144 | -243 | N/A |
| Other Working Capital | -1,523 | -2,554 | 2,678 | 249 | -6,316 |
| Other Operating Activity | 22,153 | 17,583 | 10,423 | 8,101 | 15,815 |
| Operating Cash Flow | $75,954 | $98,406 | $121,611 | $-23,437 | $-86,827 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,147 | -542 | -439 | -279 | -441 |
| Investing Cash Flow | $-1,147 | $-542 | $-439 | $-279 | $-441 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 24,475 | 24,475 | 24,475 | 24,216 | N/A |
| Common Stock Issued | 733 | 670 | 444 | 365 | N/A |
| Other Financing Activity | 67,639 | -2,560 | -184 | 0 | 16,385 |
| Financing Cash Flow | $92,847 | $22,585 | $24,735 | $24,581 | $16,385 |
| Beginning Cash Position | 30,246 | 30,246 | 30,246 | 30,246 | 101,129 |
| End Cash Position | 197,900 | 150,695 | 176,153 | 31,111 | 30,246 |
| Net Cash Flow | $167,654 | $120,449 | $145,907 | $865 | $-70,883 |
| Free Cash Flow | |||||
| Operating Cash Flow | 75,954 | 98,406 | 121,611 | -23,437 | -86,827 |
| Capital Expenditure | -1,147 | -542 | -439 | -279 | N/A |
| Free Cash Flow | 74,807 | 97,864 | 121,172 | -23,716 | -86,827 |